Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase I/II study of EMB-01 in advanced or metastatic solid tumors
CTR20190241Phase 2Active
- Sponsor
- EpimAb Biotherapeutics
- Start
- Feb 2019
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of emb-01 in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC), colorectal cancer (CRC), gastric cancer (GC), hepatocellular carcinoma (HCC), sponsored by EpimAb Biotherapeutics. Started Feb 2019; status: active.
02
Drugs
emb-01
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)gastric cancer (GC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20190241.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20190241.